ライフスタイル・ドラッグ(生活改善薬)の世界市場2017-2021...市場調査レポートについてご紹介

【英文タイトル】Global Lifestyle Drugs Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: An overview of lifestyle diseases

PART 06: Market landscape

Market overview
Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by therapy area

Depression
Dermatology (acne, anti-aging, and baldness)
Sexual dysfunction
Obesity

PART 09: Geographical segmentation

Lifestyle drugs market in Americas
Lifestyle drugs market in EMEA
Lifestyle drugs market in APAC

PART 10: Market drivers

Lifestyle changes
Development of novel therapeutics
Increasing demand from older population

PART 11: Impact of drivers

PART 12: Market challenges

Patent expiries
Side effects coupled with product recalls
Presence of alternative therapies and treatments

PART 13: Impact of drivers and challenges

PART 14: Market trends

Increase in M&A
Growing focus on development of drugs for new indications
Emerging lifestyle diseases

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

Allergan
BMS
Eli Lilly
Pfizer
Other prominent vendors

PART 17: Appendix

List of abbreviation

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Global lifestyle drugs market snapshot

Exhibit 02: Global lifestyle drugs market 2016-2021 ($ billions)

Exhibit 03: Opportunity analysis in global lifestyle drugs market

Exhibit 04: Five forces analysis

Exhibit 05: Pipeline analysis of vendors in Phase III

Exhibit 06: Key pipeline drugs for depression 2016

Exhibit 07: Key pipeline drugs for dermatology (anti-aging, baldness, and acne) 2016

Exhibit 08: Key pipeline drugs for sexual dysfunction 2016

Exhibit 09: Key pipeline drugs for obesity

Exhibit 10: Global depression drugs market 2016-2021 ($ billions)

Exhibit 11: Global dermatology lifestyle drugs market 2016-2021 ($ billions)

Exhibit 12: Global sexual dysfunction drugs market 2016-2021 ($ billions)

Exhibit 13: Global obesity drugs market 2016-2021 ($ billions)

Exhibit 14: Segmentation of global lifestyle drugs market by geography 2016 and 2021

Exhibit 15: Global lifestyle drugs market revenue by geography 2016-2021 ($ billions)

Exhibit 16: Market scenario in Americas

Exhibit 17: Lifestyle drugs market in Americas 2016-2021 ($ billions)

Exhibit 18: Market scenario in EMEA

Exhibit 19: Lifestyle drugs market in EMEA 2016-2021 ($ billions)

Exhibit 20: Market scenario in APAC

Exhibit 21: Lifestyle drugs market in APAC 2016-2021 ($ billions)

Exhibit 22: Impact of drivers

Exhibit 23: Impact of drivers and challenges

Exhibit 24: Competitive structure analysis of global lifestyle drugs market 2016

Exhibit 25: Competitive analysis of global lifestyle drugs market

Exhibit 26: Market penetration of various lifestyle drug manufacturers worldwide 2016

Exhibit 27: Strategic success factors of companies in global lifestyle drugs market

Exhibit 28: Allergan: Key highlights

Exhibit 29: Allergan: Strength assessment

Exhibit 30: Allergan: Strategy assessment

Exhibit 31: Allergan: Opportunity assessment

Exhibit 32: BMS: Strength assessment

Exhibit 33: BMS: Strategy assessment

Exhibit 34: BMS: Opportunity assessment

Exhibit 35: BMS: YoY and growth rate of Abilify 2013-2015 ($ billions)

Exhibit 36: Eli Lilly: Key highlights

Exhibit 37: Eli Lilly: Strength assessment

Exhibit 38: Eli Lilly: Strategy assessment

Exhibit 39: Eli Lilly: Opportunity assessment

Exhibit 40: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)

Exhibit 41: Eli Lilly: YoY and growth rate of Zyprexa 2013-2015 ($ millions)

Exhibit 42: Eli Lilly: YoY and growth rate of Strattera 2013-2015 ($ millions)

Exhibit 43: Eli Lilly: YoY and growth rate of Cialis 2013-2015 ($ millions)

Exhibit 44: Pfizer: Key highlights

Exhibit 45: Pfizer: Strength assessment

Exhibit 46: Pfizer: Strategy assessment

Exhibit 47: Pfizer: Opportunity assessment

Exhibit 48: Pfizer: YoY and growth rate of Pristiq 2013-2015 ($ millions)

Exhibit 49: Pfizer: YoY and growth rate of Zoloft 2013-2015 ($ millions)

Exhibit 50: Pfizer: YoY and growth rate of Effexor 2013-2015 ($ millions)

Exhibit 51: Pfizer: YoY and growth rate of Viagra 2013-2015 ($ millions)


【レポート販売概要】

■ タイトル:ライフスタイル・ドラッグ(生活改善薬)の世界市場2017-2021
■ 英文:Global Lifestyle Drugs Market 2017-2021
■ 発行日:2017年2月13日
■ 調査会社:Technavio
■ 商品コード:IRTNTR11351
■ 調査対象地域:世界
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。